Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6844

1.
2.

Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.

Rahman A, Henry KM, Herman KD, Thompson AAR, Isles HM, Tulotta C, Sammut D, Rougeot JJ, Khoshaein N, Reese AE, Higgins K, Tabor C, Sabroe I, Zuercher WJ, Savage CO, Meijer AH, Whyte MK, Dockrell DH, Renshaw SA, Prince LR.

Elife. 2019 Oct 15;8. pii: e50990. doi: 10.7554/eLife.50990. [Epub ahead of print]

3.

Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line.

Tong Y, Wang M, Huang H, Zhang J, Huang Y, Chen Y, Pan H.

Exp Ther Med. 2019 Nov;18(5):3793-3800. doi: 10.3892/etm.2019.8027. Epub 2019 Sep 19.

4.

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells.

Xiao J, Wang F, Lu H, Xu S, Zou L, Tian Q, Fu Y, Lin X, Liu L, Yuan P, Ni X, Ma T, Zeng F, Xue P, Xiu R, Zhang J, Ji X, Hu H, Lu S, Dai H, Li Y, Chu Q, Zhao X, Duan Q, Zhu F.

Cell Death Dis. 2019 Oct 14;10(10):777. doi: 10.1038/s41419-019-2020-4.

5.

Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

Takenaka T, Nakai S, Katayama M, Hirano M, Ueno N, Noguchi K, Takatani-Nakase T, Fujii I, Kobayashi SS, Nakase I.

Int J Pharm. 2019 Oct 11:118762. doi: 10.1016/j.ijpharm.2019.118762. [Epub ahead of print]

PMID:
31610280
6.

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.

Chih-Hsin Yang J, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33332-5. doi: 10.1016/j.jtho.2019.09.008. [Epub ahead of print] No abstract available.

7.

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.

Dal Maso A, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, Cecere FL, Del Conte A, Nardo G, Buoro V, Scattolin D, Monteverdi S, Urso L, Zulato E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Conte P, Pasello G.

Clin Lung Cancer. 2019 Aug 5. pii: S1525-7304(19)30213-X. doi: 10.1016/j.cllc.2019.07.009. [Epub ahead of print]

PMID:
31601525
8.

FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors on Non-Small Cell Lung Cancer Cells (NSCLC).

Tabtimmai L, Srisook P, Kuaprasert B, Thumanu K, Choowongkomon K.

J Biophotonics. 2019 Oct 8:e201960012. doi: 10.1002/jbio.201960012. [Epub ahead of print]

PMID:
31595681
9.

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.

Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J.

BMJ. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460.

10.

Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.

Ansari AJ, Joshi G, Yadav UP, Maurya AK, Agnihotri VK, Kalra S, Kumar R, Singh S, Sawant DM.

Bioorg Chem. 2019 Sep 26;93:103314. doi: 10.1016/j.bioorg.2019.103314. [Epub ahead of print]

PMID:
31590041
11.

Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma.

Kwok WC, Ho JCM, Tam TCC, Lui MMS, Ip MSM, Lam DCL.

Anticancer Drugs. 2019 Nov;30(10):1048-1051. doi: 10.1097/CAD.0000000000000849.

PMID:
31584455
12.

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study.

Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC.

Cancer Manag Res. 2019 Sep 19;11:8539-8546. doi: 10.2147/CMAR.S222278. eCollection 2019.

13.

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients.

Thomas P, Vincent B, George C, Joshua JM, Pavithran K, Vijayan M.

Indian J Med Res. 2019 Jul;150(1):67-72. doi: 10.4103/ijmr.IJMR_1896_17.

14.

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Gelatti ACZ, Drilon A, Santini FC.

Lung Cancer. 2019 Sep 23;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. [Epub ahead of print] Review.

15.

TNFα inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFα signaling.

Ma L, She C, Shi Q, Yin Q, Ji X, Wang Y, Fan Y, Kong X, Li P, Sun Z, Zhang X, Zhang Z, Wang J, Wang T, Xu Y, Li W.

Cancer Biol Med. 2019 Aug;16(3):606-617. doi: 10.20892/j.issn.2095-3941.2019.0011.

16.

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.

Lavacchi D, Mazzoni F, Giaccone G.

Drug Des Devel Ther. 2019 Sep 6;13:3187-3198. doi: 10.2147/DDDT.S194231. eCollection 2019.

17.

Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.

Jia Y, Zhao S, Jiang T, Li X, Zhao C, Liu Y, Han R, Qiao M, Liu S, Su C, Ren S, Zhou C.

Lung Cancer. 2019 Sep 19;137:85-93. doi: 10.1016/j.lungcan.2019.09.016. [Epub ahead of print]

PMID:
31563735
18.

BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.

Wang F, Zhang L, Sai B, Wang L, Zhang X, Zheng L, Tang J, Li G, Xiang J.

Cancer Biol Ther. 2019 Sep 27:1-11. doi: 10.1080/15384047.2019.1665952. [Epub ahead of print]

PMID:
31559898
19.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1431. doi: 10.3390/cancers11101431.

20.

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.

Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE.

Mol Pharmacol. 2019 Sep 25. pii: mol.119.117804. doi: 10.1124/mol.119.117804. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center